Bessemer Group
BMY.RT

Bessemer Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bessemer Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,488
Closed -$1K – 1714
2020
Q4 		$1K Sell
1,488
-126
-8% -$268 ﹤0.01% 1451
2020
Q3 		$4K Hold
1,614
– – ﹤0.01% 1229
2020
Q2 		$6K Hold
1,614
– – ﹤0.01% 1557
2020
Q1 		$6K Hold
1,614
– – ﹤0.01% 1491
2019
Q4 		$4K Buy
+1,614
New +$4.2K ﹤0.01% 1514

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Bessemer Group's BMY.RT Position: Q1 2021 in Review

Bessemer Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,488 shares — an estimated $1K sold.

Bessemer Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $6K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Bessemer Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Bessemer Group sold 1,488 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Bessemer Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Bessemer Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $6K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bessemer Group's 13F filing for Q1 2021, filed 13 May 2021.